Open-Label Pharmacokinetics (PK)/Safety Study of Luliconazole Solution, 10% in Distal Subungual Onychomycosis

Completed · Phase 1/Phase 2

Conditions studied: Onychomycosis

In brief

To determine the safety, tolerability, systemic exposure and pharmacokinetics of luliconazole after repeat daily topical application of Luliconazole Solution, 10% in a maximal use setting in adults with distal subungual onychomycosis of the toenails.

Key facts

Study ID

NCT01044381

Run by

Topica Pharmaceuticals

People needed

24

Starts

2010-12-01

Expected to finish

2011-05-01

Last updated by the study team

2014-11-26

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18-65 years
• Distal Subungual Onychomycosis(DSO)on both great toenails with >=50%involvement of at least 1 great toenail
• At least 4 additional toenails with DSO
• Positive KOH and culture
• Normal renal and hepatic function

You may not qualify if…

• Subjects with hypersensitivity to imidazole compounds or any other ingredient
• Subjects unwilling to refrain from use of nail cosmetics until end of study
• Subjects with symptomatic tinea pedis
• Subjects with any history of cardiac disease of cardiac rhythm abnormalities
• Female subjects who are pregnant, nursing, or planning a pregnancy
• Subjects who have not undergone the specified washout period(s) for the following or requiring the concurrent use of: topical antifungal within 4 weeks; topical anti-inflammatory, corticosteroids, topical immunomodulators within 2 weeks; systemic corticosteroids within 2 weeks; systemic immunomodulators within 4 weeks.
• Subjects receiving systemic antifungals for treatment of onychomycosis or any systemic antifungal with known activity against dermatophytes within the previous 12 weeks or 5 half-lives of the drug, whichever is longer
• Subjects receiving any other treatment/therapy for the onychomycosis not previously mentioned (e.g., laser treatment) within 4 weeks
• Subjects with a history of significant internal disease or with a life threatening condition within the last 6 months
• Subjects with anatomic abnormalities of the toe(s) and or toenails
• Subject who have donated or lost a large volume of blood (\~500 mL or more, during the previous 6 weeks
• Subjects with a recent history of or currently known to abuse drugs or alcohol
• Subjects currently participating in another investigational medication or device study or have participated in a clinical trial within 30 days or five half-lives of the test medication

Where it is running

• J&S Studies — College Station, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.